Randomized trial evaluates efficacy and safety of therapies in advanced ovarian cancer, suggesting optimal regimens remain undefined.
The integration of poly(ADP-ribose) polymerase inhibitors (PARPi), immune checkpoint inhibitors, and anti-angiogenics has transformed first-line maintenance for advanced ovarian cancer (AOC), yet optimal regimens across biomarker profiles remain undefined. Aim is To evaluate the comparative efficacy and safety of frontline maintenance therapies across homologous recombination deficiency (HRD) and BRCA mutation (BRCAm) profiles in AOC.
No takes yet. Share an insight, caveat, or question.
Falodia et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: